
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934**

Date of Report: July 29, 2021

Commission File Number: **001-40377**

Valneva SE

(Translation of registrant's name into English)

6 rue Alain Bombard

44800 Saint-Herblain, France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [] Form 40-F []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

On July 29, 2021, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit

99.1 [Press release dated July 29, 2021](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Valneva SE
(Registrant)

Date: July 29, 2021

/s/ Thomas Lingelbach
Thomas Lingelbach
Chief Executive Officer and President

Valneva Appoints Peter Buhler as Chief Financial Officer

Saint-Herblain (France), July 29, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced the appointment of Peter Buhler as Chief Financial Officer (CFO) and Management Board member.

Peter has over 20 years of experience in the strategic and financial leadership of life science and technology companies. He currently serves as Chief Financial Officer of Nasdaq-listed Swiss diagnostics company Quotient, where he strengthened the balance sheet, raising close to \$200 million in cash. Prior to Quotient, Peter served as Group CFO of Zaluvida AG and as Group CFO of Stallergenes Greer Plc, where he led a complex merger project to combine a French and US Company. Prior to this, Peter held senior finance roles at Eli Lilly, Merck Serono and Logitech. Peter is a Swiss Certified Accountant and holds an Executive MBA from the SBS Swiss Business School.

To ensure business continuity and transition, David Lawrence, Acting CFO of Valneva, has agreed to continue supporting Valneva until late 2021. It is expected that Peter will be joining Valneva within the next six months.

Thomas Lingelbach, Chief Executive Officer of Valneva, said, “We are delighted that Peter will join Valneva. With his proven expertise in financial and strategic management and, most notably, his U.S. and Nasdaq experience, he will be a great addition to our Management Team. I would also like to thank David for his ongoing commitment, continuous dedication and major contribution in his current transitional role as acting CFO.”

Peter Buhler stated, “I look forward to joining Valneva’s Management Board and leading its finance organization to contribute to Valneva’s future success as the company progresses to the next stage of its strategy.”

About Valneva SE

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. It then applies its deep understanding of vaccine science, including its expertise across multiple vaccine modalities, as well as its established vaccine development capabilities, to develop prophylactic vaccines to address these diseases. The Company has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

Media & Investor Contacts

Laëtitia Bachelot-Fontaine

VP Global Communications & European Investor Relations

M +33 (0)6 4516 7099

laetitia.bachelot-fontaine@valneva.com

Joshua Drumm, Ph.D.

VP Global Investor Relations

M +001 917 815 4520

joshua.drumm@valneva.com